Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Searching for synergy: Identifying optimal antiviral combination therapy using Hepatitis C virus (HCV) agents in a replicon system.

Antiviral research - 1 Oct 2017

Pomeroy Justin J, Drusano George L, Rodriquez Jaime L, Brown Ashley N

Abstract excerpt

Direct acting antiviral agents (DAAs) are potent inhibitors of Hepatitis C virus (HCV) that have revolutionized the treatment landscape for this important viral disease. There are currently four classes of DAAs that inhibit HCV replication via distinct mechanisms of action: nonstructural protein (NS) 3/4a protease inhibitors, NS5A inhibitors, NS5B nucleoside polymerase inhibitors, and NS5B non-nucleoside...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Drug Synergism

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Therapy, Combination

Share to Hepacivirus

Share to Hepatitis C

Share to Protease Inhibitors

Share to Replicon

Share to Virus Replication

Source

Open in PubMed Open full text

Identifiers

PMID: 28882564
DOI: 10.1016/j.antiviral.2017.09.001
PMCID: PMC5654674

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Searching for synergy: Identifying optimal antiviral combination therapy using Hepatitis C virus (HCV) agents in a replicon system.PMID 28882564Read ↗

Required concentration index quantifies effective drug combinations against hepatitis C virus infection.Semantic proximity Read ↗

Required concentration index quantifies effective drug combinations against hepatitis C virus infectionSemantic proximity Read ↗

Rational design of antiviral drug combinations based on equipotency using HCV subgenomic replicon as an in vitro model.Semantic proximity Read ↗

Required concentration index quantifies effective drug combinations against hepatitis C virus infectionSemantic proximity Read ↗

Synergistic Antiviral Activity of Human Interferon Combinations in the Hepatitis C Virus Replicon SystemSemantic proximity Read ↗

HCV Replicon Systems: Workhorses of Drug Discovery and Resistance.Semantic proximity Read ↗

Effect on Hepatitis C Virus Replication of Combinations of Direct-Acting Antivirals, Including NS5A Inhibitor DaclatasvirSemantic proximity Read ↗

Identification of novel antiviral drug combinations in vitro and tracking their developmentSemantic proximity Read ↗

Mathematical modeling of multi-drugs therapy: a challenge for determining the optimal combinations of antiviral drugs.Semantic proximity Read ↗

Modeling Suggests a Mechanism of Synergy Between Hepatitis C Virus Entry Inhibitors and Drugs of Other ClassesSemantic proximity Read ↗

The Combination of Molnupiravir with Nirmatrelvir or GC376 Has a Synergic Role in the Inhibition of SARS-CoV-2 Replication In VitroSemantic proximity Read ↗

Sofosbuvir (SOF) Suppresses Ledipasvir (LDV)-resistant Mutants during SOF/LDV Combination Therapy against Genotype 1b Hepatitis C Virus (HCV).Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.